CBLL
Ceribell, Inc.Press releases and events scraped from the company's investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Recent news
| Date | Headline |
|---|---|
| 2026-06-08 |
Ceribell Announces New Critical Care Medicine Publication Reinforcing Link Between Seizure Burden Measured by Clarity AI Algorithm and Neurological Outcomes
Study published in leading critical care journal shows that higher AI-detected seizure burden is associated with increased odds of disability, further demonstrating the utility of the Ceribell System as a clinical decision-making tool SUNNYVALE, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- CeriBell, |
| 2026-05-20 |
Ceribell to Participate in the William Blair 46th Annual Growth Stock Conference
SUNNYVALE, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, will present |
| 2026-05-11 |
Ceribell Reports First Quarter 2026 Financial Results
SUNNYVALE, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the first quarter ended March 31, |
| 2026-04-29 |
Ceribell to Participate in the Bank of America Securities 2026 Health Care Conference
SUNNYVALE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, and Scott |
| 2026-04-20 |
Ceribell to Report First Quarter 2026 Financial Results on May 11, 2026
SUNNYVALE, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the first |
| 2026-02-24 |
Ceribell Reports Fourth Quarter and Full Year 2025 Financial Results
SUNNYVALE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the fourth quarter and full year |
| 2026-02-18 |
Ceribell to Participate in Upcoming March Investor Conferences
SUNNYVALE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced the company will be participating in two upcoming |
| 2026-02-10 |
Ceribell to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
SUNNYVALE, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the fourth |
| 2026-01-05 |
Ceribell Receives FDA Breakthrough Device Designation for LVO Stroke Detection and Monitoring Solution
Clearance would position the Ceribell System as the first and only point-of-care electroencephalography (EEG) technology to aid in detection and monitoring of Large Vessel Occlusion (LVO) stroke in the hospital setting SUNNYVALE, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. |
| 2025-12-30 |
Ceribell to Participate in the 44th Annual J.P. Morgan Healthcare Conference
SUNNYVALE, Calif., Dec. 30, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, will |
Past events
Source: https://investors.ceribell.com/